Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Carbapenem-Nonsusceptible Gram-Negative Pathogens in ICU and Non-ICU Settings in US Hospitals in 2017: A Multicenter Study.

McCann E, Srinivasan A, DeRyke CA, Ye G, DePestel DD, Murray J, Gupta V.

Open Forum Infect Dis. 2018 Sep 21;5(10):ofy241. doi: 10.1093/ofid/ofy241. eCollection 2018 Oct.

2.

Stability and recovery of DIFICID(®) (Fidaxomicin) 200-mg crushed tablet preparations from three delivery vehicles, and administration of an aqueous dispersion via nasogastric tube.

Tousseeva A, Jackson JD, Redell M, Henry T, Hui M, Capurso S, DeRyke CA.

Drugs R D. 2014 Dec;14(4):309-14. doi: 10.1007/s40268-014-0067-3.

3.

Response to Surawicz et al.

Gorbach S, DeRyke CA, Sears P.

Am J Gastroenterol. 2014 Oct;109(10):1684. doi: 10.1038/ajg.2014.224. No abstract available.

PMID:
25287090
4.

The impact of initial antibiotic therapy (linezolid, vancomycin, daptomycin) on hospital length of stay for complicated skin and soft tissue infections.

Szczypinska E, Velazquez A, Salazar D, Deryke CA, Raczynski B, Wallace MR.

Springerplus. 2013 Dec 30;2:696. doi: 10.1186/2193-1801-2-696. eCollection 2013.

5.

Daptomycin non-susceptible Staphylococcus aureus at a US medical centre.

Velazquez A, DeRyke CA, Goering R, Hoover V, Wallace MR.

Clin Microbiol Infect. 2013 Dec;19(12):1169-72. doi: 10.1111/1469-0691.12171. Epub 2013 Mar 11.

6.

Performance of a vancomycin dosage regimen developed for obese patients.

Reynolds DC, Waite LH, Alexander DP, DeRyke CA.

Am J Health Syst Pharm. 2012 Jun 1;69(11):944-50. doi: 10.2146/ajhp110324.

PMID:
22610026
7.

Over-treatment of carbapenemase-producing Enterobacteriaceae.

Rihani DS, Wallace MR, Sieger BE, Waite RA, Fox M, Brown SA, Deryke CA.

Scand J Infect Dis. 2012 May;44(5):325-9. doi: 10.3109/00365548.2011.638318. Epub 2011 Dec 27.

PMID:
22200121
8.

Colistin dosing and nephrotoxicity in a large community teaching hospital.

Deryke CA, Crawford AJ, Uddin N, Wallace MR.

Antimicrob Agents Chemother. 2010 Oct;54(10):4503-5. doi: 10.1128/AAC.01707-09. Epub 2010 Jul 26.

9.

Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem.

Nicasio AM, Quintiliani R Jr, DeRyke CA, Kuti JL, Nicolau DP.

Ann Pharmacother. 2007 Jun;41(6):1077-81. Epub 2007 May 1.

PMID:
17472997
10.

Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.

DeRyke CA, Kuti JL, Nicolau DP.

Diagn Microbiol Infect Dis. 2007 Jul;58(3):337-44. Epub 2007 Mar 9.

PMID:
17350206
12.
13.

Is all free time above the minimum inhibitory concentration the same: implications for beta-lactam in vivo modelling.

DeRyke CA, Nicolau DP.

Int J Antimicrob Agents. 2007 Mar;29(3):341-3. Epub 2007 Jan 16.

PMID:
17223318
14.

parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones.

Sun HK, Du X, DeRyke CA, Doern GV, Nicolau DP.

Int J Antimicrob Agents. 2007 Feb;29(2):230-2. Epub 2007 Jan 3. No abstract available.

PMID:
17204405
15.
17.

Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.

DeRyke CA, Kuti JL, Mansfield D, Dana A, Nicolau DP.

Am J Health Syst Pharm. 2006 Apr 15;63(8):750-5. No abstract available.

PMID:
16595817
18.
19.

Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia.

DeRyke CA, Lodise TP Jr, Rybak MJ, McKinnon PS.

Chest. 2005 Sep;128(3):1414-22.

PMID:
16162737
20.

Questioning the paradigm: monotherapy vs combination antimicrobial therapy for treatment of Pseudomonas aeruginosa.

DeRyke CA, Kuti JL, Nicolau DP.

Conn Med. 2005 May;69(5):271-5. Review. No abstract available.

PMID:
16114642
21.

Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patient.

DeRyke CA, Maglio D, Nicolau DP.

Expert Opin Pharmacother. 2005 Jun;6(6):873-89. Review.

PMID:
15952918

Supplemental Content

Loading ...
Support Center